Overview

Open-Label Extension Study of MCS-2 in the Treatment of Lower Urinary Tract Symptoms

Status:
Completed
Trial end date:
2014-06-01
Target enrollment:
0
Participant gender:
Male
Summary
This is an open-label extension study of another study protocol, MCS-2-TWN-a. Subjects who have completed the 12-week treatment and procedures under the protocol MCS-2-TWN-a will be eligible for this study.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Health Ever Bio-Tech Co., Ltd.
Criteria
Inclusion Criteria:

- Subject has completed 12 weeks of treatment under the protocol MCS-2-TWN-a.

- Subject is able to understand and willing to conform to the study procedures and has
signed the informed consent form for participation in this extension study.

Exclusion Criteria:

- Subject has severe LUTS at the last visit under the protocol MCS-2-TWN-a.

- Subject is considered ineligible for the study by the investigator(s).